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Abstract Background The launch of imatinib has turned
chronic myeloid leukaemia (CML) into a chronic illness
due to the dramatic improvement in survival. Several
recent studies have demonstrated that poor adherence to
imatinib may hamper the therapeutic outcomes and result
in increased medical expenditures, whilst research on
exploring the reasons for non-adherence to imatinib is still
limited. Objective This study aimed to explore the expe-
rience of patients as they journey through their CML
treatments and associated imatinib utilisation in order to
understand the perceptions, attitudes and concerns that may
influence adherence to imatinib treatment. Setting This
study was conducted at oncology outpatient clinics in a
medical centre in southern Taiwan. Methods CML patients
who regularly attended the oncology outpatient clinics to
receive imatinib treatment from October 2011 to March
2012 were invited to participate in the study. Semi-struc-
tured face-to-face interviews were used to explore patients’
experiences and views of their treatment, their current
CML status and CML-related health conditions, their
concerns about imatinib treatment and imatinib-taking
behaviours. Patient interviews were recorded, transcribed
verbatim and thematically analysed using the constant
comparison approach. Main outcome measure Themes
related to patients’ views of the disease and health condi-
tions, worries and concerns influencing imatinib utilisation
behaviours are reported. Results Forty-two CML patients
participated in the interviews. The emerging themes
included: acceptance of current disease and health status,
misconceptions about disease progression, factors associ-
ated with adherence to imatinib, concerns and management
of adverse drug effects. Participants regarded CML as a
chronic disease but had misconceptions about disease
progression, therapeutic monitoring, resistance to imatinib
and symptoms of side effects. Participants were generally
adherent to imatinib and favoured long-term prescriptions
to avoid regular outpatient visits for medication refills.
Experiencing adverse effect was the main reason influ-
encing adherence and led to polypharmacy. Most partici-
pants altered medicine-taking behaviours to maintain long-
term use of imatinib. Conclusion Taiwanese CML patients
are adherent to imatinib but report changing their medi-
cation-taking behaviour due to adverse drug effects and
associated polypharmacy. Patients’ misconceptions of the
disease and medication suggests that it is necessary to
improve communication between patients and healthcare
professionals. Routinely providing updated information as
part of the patient counselling process should be considered
as a means of improving this communication.
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Impact of findings on practice statements
• Despite being adherent to the treatment, CML patients
in Taiwan lack sufficient knowledge of disease pro-
gression, therapeutic effects, symptoms and manage-
ment of side effects.
• Adverse drug effects and associated polypharmacy are
the key concerns that impact on patients’ adherence and
alter their medicine-taking approach to maintaining
long-term use of imatinib.
• Healthcare professionals can help improve adherence
and patient care by offering patients information on
interpreting clinical indicators, symptoms of adverse
effects and strategies to manage adverse effects.
Introduction
Adherence has been defined by the World Health Organi-
sation as the extent to which a person’s behaviour corre-
sponds with the agreed recommendations of a healthcare
provider [1]. Non-adherence to pharmacotherapy has been
reported to be associated with increased healthcare costs
due to poor health outcomes and a waste of drugs. Non-
adherence presents a major problem in health care [2, 3]
across different ages and in all therapeutic areas [4, 5]. This
is especially true for chronic diseases where the non-
adherence rate to long-term therapy is estimated to be 50 %
in developed countries [6, 7], and is even higher in
developing countries [1]. Non-adherence is also the main
reason why patients fail to meet the therapeutic targets for
chronic diseases thus resulting in suboptimal health out-
comes [8, 9].
With the rapid development of cancer treatments, con-
cerns about the challenges in maintaining adherence (tak-
ing medication as prescribed) and persistence (continuing
treatment for the prescribed duration) to long-term oral
cancer therapies has also been raised [10]. Although the
adherence rate for oral cancer therapies is superior to that
for oral non-cancer therapies possibly due to the higher
motivation of cancer patients and their preference to oral
therapies [11, 12], the adherence and persistence rates for
oral cancer medications are generally lower in real world
settings compared to those in clinical trials, especially for
chronically administered medications [13–15]. The average
adherence rate for oral anticancer therapies among adults is
estimated to be 79 % [16], but it ranges between 0 and
83 % [17] due to different measurements and definitions of
adherence.
Since the launch of imatinib, it has transformed chronic
myeloid leukaemia (CML) from an inexorably fatal illness
to a chronic illness due to its dramatic improvements on
survival [18]. Intentional non-adherence to this potentially
lifesaving therapy seem counterintuitive, yet several recent
studies have demonstrated that non-adherence to imatinib
is frequent, and thus may significantly affect the thera-
peutic outcomes [18, 19] and lead to increased medical
expenditures [20]. So far, few studies have explored the
factors associated with non-adherence to imatinib therapy
in Western countries [21, 22].
The WHO has categorised the determinants of non-
adherence to medicines into five dimensions: social and
economic, health system-related, therapy-related, condi-
tion-related, and patient-related [1]. Previous studies have
predominantly evaluated non-cancer chronic conditions
and identified several determinants to non-adherence [7]:
complexity of therapy, duration of therapy, characteristics
of the disease [23], adverse drug reactions [1, 24], cost of
treatment [23, 25], characteristics of health service provi-
sion, interaction between the prescriber and patient [26],
prescribers’ follow-up [27], multiple providers [26] socio-
economic variables [1], multiple medication [26], the
patients’ own view of the required therapy [24, 28, 29] and
unintended non-adherence [28].
In Taiwan, CML treatment is delivered under the cov-
erage of the Taiwan National Health Insurance (NHI),
where imatinib and other second-generation tyrosine
kinase inhibitors (TKIs) are available for CML patients
who are exempted from co-payment. Similar to other
developed countries, since the launch of imatinib in Tai-
wan in 2003, the survival rate of CML patients has been
dramatically improved. However, little is known about
Taiwanese CML patients’ adherence to imatinib and the
factors that may influence adherence to this treatment
regimen.
Aim of the study
This study explored CML patients’ experiences of treat-
ment processes and use of imatinib, and aimed to under-
stand patients’ perceptions, attitudes and concerns that may
influence adherence to imatinib treatment.
Methods
Study design and setting
This study adopted a qualitative approach in order to
explore patients’ complex medication-taking behaviours
and attitudes [30]. Semi-structured face-to-face interviews
were conducted from October 2011 to March 2012 at
oncology outpatient clinics in a medical centre in southern
Taiwan after being granted ethical approval from the
Institutional Review Board of the research centre
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(reference: KMUH-IRB-20110160). The research centre,
together with other two medical centres, provides tertiary
care for about 3.26 million inhabitants in southern Taiwan,
and there are about 6,000 outpatients visiting the research
centre daily. At the time of the research, it was estimated
that 120 CML patients received treatment there, and about
48 patients were regularly followed up and treated with
imatinib.
Participants
A purposive sample of CML patients who received imati-
nib treatment was selected as the study population. Eligible
patients included those who (1) were diagnosed with CML,
(2) regularly visited oncology outpatient clinics to receive
imatinib treatment, (3) were able to communicate using
either Mandarin or Taiwanese, and (4) without any cog-
nitive impairment. Patients were referred to an onsite
research pharmacist (Chen TC) by physicians and invited
to participate in this study. The original plan was to
interview 40 CML patients visiting the research centre or
until theme saturation was reached.
Data collection
Semi-structured interviews were conducted by a research
pharmacist (Chen TC) in a quiet room near the clinic
before or after patients’ appointments using a pre-piloted
interview schedule which contained open-ended questions
about treatment and disease course (‘‘Appendix’’). The
interview schedule was developed by reviewing published
literature [21, 31] and refined after obtaining expert opin-
ion. The pilot study involved three volunteers and three
CML patients to ensure the feasibility of the interview
schedule, and the pilot results of the CML patients were
also included in the data analysis.
Participants were informed of the purpose, interview
process and the approximate duration of the interview
(30 min). Moreover, consent to participate in the interview
and permission to audio-record the interview were
obtained. In addition to this, participants’ demographic and
socio-economic data were collected using a short ques-
tionnaire and the imatinib treatment history was recorded
by reviewing individual patient’s medical charts.
Data analysis
All interviews were recorded, transcribed verbatim and
analysed by two researchers (Chen TC and Chen LC)
independently using a constant comparison approach until
the saturation of emerging themes [32] was achieved and
no new issues were identified. Consensus on themes was
reached by discussions within the research team.
Results
Participants’ characteristics
Overall, 50 CML patients were invited and 42 (aged
between 20 and 80 years old) participated in the inter-
views. Most participants were male (n = 23) with no other
co-morbidity (n = 32) and they were diagnosed and treated
with imatinib at the chronic phase of CML (n = 35). All
participants were receiving imatinib treatment at the time
of interview, and 36 participants had been regularly fol-
lowed for more than 18 months. The majority of partici-
pants (n = 36) achieved complete cytogenetic remissions
at the 18th month of imatinib treatment, yet some (n = 13)
had experienced CML progression to accelerated or blast
phase during treatment (Table 1).
The main themes related to participants’ views of the
disease and health conditions, worries and concerns influ-
encing imatinib utilisation behaviours including acceptance
Table 1 Characteristics of participants
Characteristic Category Number (%)
Gender Male 23 (54.8)
Female 19 (45.2)
Agea Over 50 22 (52.4)
Under 50 20 (47.6)
Employment status Employed 25 (59.5)
Unemployed 1 (2.4)
Housekeeper 6 (14.3)
Retired 9 (21.4)
Student 1 (2.4)
Marriage status Single 12 (28.6)
Married 25 (59.5)
Widowed 3 (7.1)
Divorce 2 (4.8)
Use of imatinib for
more than 18 months
36 (85.7)
Imatinib utilisation Prescription interruptionc 12 (28.6)
PPR more than 90 %d 38 (90.5)
Disease phase at diagnosis Chronic phase 35 (83.3)
Accelerated or blast phase 7 (16.7)
Experience of progressionb 13 (31.0)
Treatment effect CCyR at the 18th monthe 36 (90.0)
MMR at the 18th monthf 33 (84.6)
a Mean age and standard deviation: 50.0 ± 16.0 years
b Progression to accelerate or blast phase
c Prescription interruption: any gap of prescription covering days between
two consecutive imatinib prescriptions for more than 30 days
d PPR prescription possession ratio, which refers to the proportion of
medication covering days over the treatment period
e CCyR complete cytogenetic remissions
f MMR major molecular response
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of current disease and health status, misconceptions about
disease progression, factors associated with adherence to
imatinib, concerns and management of adverse drug
effects.
Acceptance of current disease and health status
Most participants perceived CML as a severe type of cancer
which is easy to progress or metastasise and difficult to treat.
Having received imatinib treatment, most participants
accepted the reality, were satisfied with their current health
status and considered their health conditions not much dif-
ferent from normal people in terms of daily activities.
‘‘As time passed, I have learned and understood all
the conditions. Psychologically, I don’t feel myself
different from other people. So far, it (the disease) is
well controlled, no unexpected situation, just have to
take medicines every day.’’ [A07]
Most participants regarded CML as a ‘chronic disease’ and
hoped to maintain a stable control of the disease in the long
term. They were satisfied with improvement in disease-related
fatigue after receiving imatinib treatment and hence being
able to maintain body functions and carry out daily activities
(e.g. returning to work, sharing family child-care and
housekeeping responsibilities) and relieve burden from carers.
‘‘I exercise a lot and keep a normal health condition.
My wife is at work, I am the ‘house husband’ and I
have being keeping myself very busy. I just came to
pick up my medicines this morning, but the nurse
insisted that I need to have a regular check, that’s
strange, I can’t see why it’s necessary.’’ [A15]
However, those who were seeking employment or holding
future career plans still felt unproductive and oppressed as
they were conscious of their limited life expectancy and the
interruptions in their daily routine as a consequence of
regular outpatient visits. One of the main concerns for
participants was the disability and financial burden due to
the deterioration of the disease.
‘‘Our company is conducting several big projects
overseas, such as the manufacture in Vietnam; I have
to decline the project because I have my regular
appointments.’’ [A06]
Misconceptions about disease progression
The complete molecular response of CML treatment is
defined as undetectable BCR-ABL transcripts, and the
long-term therapeutic target for CML treatment is to
maintain molecular response but only cytogenetic
response. However, except for the physical and
psychological discomforts, most participants were unclear
about indicators of disease progression and therapeutic
targets. Of the routine haematological tests, white blood
cell count was found to be the most frequently referred
parameter for disease status. Participants often regarded
‘increased complete blood cell counts’ as the proliferation
of cancer cells and a metaphor for metastasis.
‘‘It (the white cell) grows very quickly and the
number multiplies in hundreds of thousands, if
treatment can’t catch up (to kill cancer cells), then the
quicker it grows, the faster the caner spreads.’’ [A09]
Some participants expressed that ‘no bad cell’ or ‘no
Philadelphia chromosome’ represents a controlled disease
condition after bone marrow biopsy. In addition, recurrent
lesions gene (BCR-ABL transcript) tested by polymerase
chain reaction (PCR) was seen as the sign of relapse by some
participants, although the rising levels may merely indicate a
loss of molecular response to treatment [33]. Even some
participants who achieved complete molecular remission
misunderstood that CML has an ‘incubation period’ and
thought their condition was only temporarily under control.
‘‘The doctor said my current condition is good
because the molecular and haematology tests are
beyond the scale. However, it doesn’t mean I have no
‘bad cell’, that’s the limitations of the tests. I did have
a bone marrow test before, but not in the past two
years. I hope I can have a bone marrow test, it’s more
accurate.’’ [A11]
Bleeding was perceived to be the most commonly mentioned
disease-related symptom, and participants generally avoided
cuts and were cautious about wound-related bleeding and
infections. Participants often had the misconception that
blood loss via blood test or bleeding wounds might weaken
their immune system, and increase susceptibility to ailments
(such as the common cold). Being anxious about disease
progression, participants were prone to react to the symp-
toms, which then led to frequent visits to emergency rooms
or higher tier of medical facilities (e.g. medical centre).
‘‘If I got a cut, I used to recover within a day or two,
but since I took this medicine, oh my God even with a
minor cut, I have to visit surgeon and get both pills
and ointment! Sometimes, I get antibiotic injections,
three continuous injections to get rid of the germs (to
avoid cellulitis), I am so scared!’’ [A31]
Factors associated with adherence to imatinib
Emerging themes from the interviews revealed patients’
beliefs on the efficacy of imatinib. Most participants
experienced a rapid drop of white blood cell counts below
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the normal range after treatment, and believed in the effi-
cacy of imatinib to control CML. In particular, those who
received other therapies (e.g. interferon and chemotherapy)
prior to imatinib regarded it superior to other treatments
due to the advantages of low toxicity, mild adverse effects
and oral route of administration. Therefore, most partici-
pants expressed that they would not stop, change or reduce
the imatinib dose. Furthermore, participants suggested that
they favoured long-term prescriptions for the maintenance
of refills in order to avoid regular outpatient visits.
‘‘I used to have interferon, but this (imatinib) tiny
tablet is much better, as you can’t have interferon
injections for ten years!… However, this long-term
medicine is for chronic disease, a two-week schedule
just passes too quickly, we should be allowed to have
a long-term drug supply and only come to visit the
doctor when we don’t feel right.’’ [A15]
Although participants were generally adherent to imatinib
treatment, their concerns about the potential ‘resistance’
also influenced their medication behaviours. Participants
were aware that long-term imatinib treatments could lead to
resistance, but they had adopted the concept of anti-
microbial resistance mechanism and believed that interrupt-
ing or changing medications would result in resistance to
imatinib. In contrast to other chronic conditions, we found
that participants seldom used traditional Chinese medicine
or herbal medicine due to the concern that drug–drug or
drug-food interactions might reduce the efficacy of imatinib.
‘‘I feel resistance could happen after long-term use of
drugs. I don’t have any medical concepts, but similar
to ‘viruses’, virus resistance develops after long-term
use of drugs, if we don’t take the drugs appropri-
ately.’’ [A22]
Concerns and management of adverse drug effects
Imatinib-related adverse effects were perceived to be the
key concern of treatment. It was participants’ general view
that the potential life-long treatment would lead to further
harm to their health. Some participants even perceived the
incidence of side effect as an indicator for disease pro-
gression. In addition, they often mistook the abnormal
laboratory results or symptoms of imatinib-related adverse
effects for occurrences of new diseases before the adverse
effects were confirmed by physicians. Some participants
complained that they lacked relevant information to mon-
itor the adverse effects.
‘‘The problems appeared one by one after different
tests, and it was only until recently I realised they are
the side effects of drugs.’’ [A05]
‘‘…However, we worry the long-term use of Western
medicine will damage liver or kidney, some doctors
would test it (liver or kidney functions) but some
won’t. How supposedly should we know whether to
test it or not? But we definitely worry about it.’’
[A03]
Imatinib-related adverse effects were the most common
reason for participants altering their treatment. To cope
with the adverse effects, participants either reduced the
dose of imatinib or adopted other approaches such as
taking imatinib with or soon after a meal to reduce
uncomfortable nausea or vomiting, or to take imatinib
before bedtime rather than in the morning to avoid the
uncomfortable vertigo (which often occurs half to two
hours after imatinib intake).
‘‘I changed to take the medicine before bed-time or
after a meal. If I take it with an empty stomach, I will
definitely vomit it out in ten minutes.’’ [A18]
In addition to imatinib-related adverse events, it was found
that detrimental impacts associated with ‘polypharmacy’
for managing imatinib-related adverse events also worried
participants. Most symptoms commonly raised by partic-
ipants (e.g. oedema, nausea, vomiting, diarrhoea, insomnia,
muscle pain, muscle cramps, poor appetite, itch and rash)
are generally mild and can be managed by other oral
medicines. However, some participants doubted whether
long-term intake of the ‘rescue medicines’ for relieving the
imatinib-related side effects was necessary, and worried
about other possible adverse effects associated with taking
too many rescue medicines, e.g. diuretics-related nocturnal
frequency and nephrotoxicity, zolpidem-related sleepwalk
and non-steroidal anti-inflammatory drugs related stomach
upsets.
‘‘The doctor prescribed a (diuretic) tablet once a day
for me, but I only took half of it per day, because I
worry long-term use of it will damage my kidney.’’
[A02]
Discussion
This study found that participants who received routine
imatinib treatment accepted CML as a chronic disease and
were generally adherent to imatinib treatment. However,
patients’ knowledge of their disease progression, thera-
peutic monitoring indicators, resistance to treatment and
symptoms of side effects were not exactly correct. These
perceptions increased patients’ concerns on disease pro-
gression and potentially incurred more medical resources,
but the worries on poor treatment effects associated with
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resistance to imatinib also reinforced good adherence and
beliefs on efficacy of imatinib. Concern on the adverse
effects and associated polypharmacy was the main reason
that patients altered imatinib therapy.
The patient journey during their treatment of CML
presents a similar emotional pattern as manifested in other
types of cancer treatment. Macdonald et al. [31] suggest a
five-stage treatment journey for metastatic gastrointestinal
stromal tumour patients which includes ‘crisis’ at diagno-
sis, ‘hope’ at initial treatment, ‘adoption’ at response and
monitoring, ‘new normal’ under chronic management, and
‘uncertainty’ at resistance or progression stage. As this
study recruited CML patients who routinely received i-
matinib treatment, it is not surprising to observe that they
had accepted the chronicity nature of the disease and
adapted to the treatment routine, two key stages consti-
tuting participants’ adherence to treatment.
Despite being adherent to the treatment, participants
lacked sufficient knowledge of disease progression and
therapeutic effects and hence were prone to misinterpreting
laboratory results and judging the treatment outcome by the
occurrence of symptoms, adverse effects and daily activi-
ties (function of life). This also indicates a communication
gap between CML patients and healthcare professionals.
For example, PCR offered a parameter for monitoring
long-term treatment response but the appearance of recur-
rent lesions gene in PCR does not necessarily mean that a
relapse will occur. Resistance of imatinib is caused by gene
mutation. Patients’ misconceptions about the condition of
the disease might cause unnecessary anxiety, change
medication-taking behaviours and even worsen adherence.
A previous study has shown that establishing patient-phy-
sician trust and communication can have a positive impact
on adherence [21].
Experiences of the treatment effects and knowledge of
consequences caused by non-adherence to imatinib are
important factors contributing to CML patients’ adherence
to imatinib; and imatinib-related side effects and poly-
pharmacy are the key concerns that may jeopardise
adherence. Most findings from the present study are con-
sistent with those from a previous study which was
reported by Eliasson et al. [21] that took an in-depth
approach to investigate the reasons for non-adherence to
imatinib in a small target group of CML patients.
Eliasson et al. [21] enrolled 87 CML patients who had
been prescribed imatinib for a minimum of 2 years at a
teaching hospital in England, and monitored their imatinib
taking for 3 months using a medication event monitoring
system (MEMS, an electronic device fitted in the cap of the
medication bottle to record the opening time and date), and
21 in-depth interviews were then conducted. Seventeen
patients were categorised as non-adherent as their MEMS
showed an adherence rate of less than 90 %; they generally
regarded that missing several does will not damage the
treatment efficacy. However, an adverse drug effect is still
the main reason to non-adherence for long-term imatinib
users.
A variety of methods have been used to measure adher-
ence to imatinib in previous studies. For instance, the
microelectronic monitoring systems [18], Basel’s assess-
ment of adherence scale, pill counts, scheduled appointments
ratio [19], prescribing interruption and medication posses-
sion ratio [20], and self-reported visual analogue scale [19]
were referred to. However, due to the complexity of adher-
ence, there is currently no gold standard to measure adher-
ence to imatinib in clinical practice [1, 34] and no conclusive
operational definition of good adherence [16]. Based on our
findings, it is significant to consider and measure imatinib
adherence in multiple domains such as medication behaviour
(e.g. delay medication taking), administration routes (e.g.
oral taken) and individual beliefs of disease and treatments.
In addition, previous studies have also showed that CML
patients’ adherence to imatinib can also be influenced by
increased concomitant medications and adverse effects [18,
20]. In the stage of severe CML (accelerate and blast
phases), prescribing higher doses of imatinib would cause
more adverse effects and poor adherence [35]. For patients
with multiple co-morbidities, adherence might be reduced
due to adverse effects, drug–drug interaction or polyphar-
macy. Previous research has suggested that finding ways to
deal with side effects and using prompts as reminders to
take the medicine are factors associated with good adher-
ence to imatinib [21].
From the patients’ perspective, self-monitoring and self-
managing symptoms of adverse effects were the easiest
way to manage imatinib-related adverse effects [36]. Their
experience also suggests that adopting an alternative
medication-taking approach might relieve nausea, vomiting
and vertigo and exercise can lessen oedema and muscle
pain, thus reducing patients’ anxiety and avoiding the
consequences of polypharmacy.
This study also suggests that the delivery of healthcare
information and communication between patients and
healthcare professionals need to be improved. Areas such as
patients’ misconceptions about disease progression, moni-
toring effects from treatment and resistance of imatinib
require further clarification, and healthcare professionals
should improve patients’ knowledge on making appropriate
judgment regarding effects from treatment, dealing with
missing doses and adverse effects at the occasions of face-
to-face patient counselling or medicine utilisation review,
thus reinforcing the importance of adherence.
To the best of our knowledge, this is the first study using
an in-depth qualitative approach to explore Taiwanese
CML patients’ perceptions on imatinib treatment. This
study recruited almost all active patients of the outpatient
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clinic and took a wider scope to explore patients’ treatment
journey and experiences. The results inform the key issues
of adherence to imatinib and reveal the information gap
between patients and healthcare professionals.
However, the transferability of the results is uncertain as
this study only involves CML patients who were regularly
followed up in the hospital, and hence patients might
experience better treatment effects and have better health
awareness. The perceptions of those who were newly
diagnosed with the disease or those suffering from poor
treatment effects are still not clear. In addition, caution
needs to be taken in interpreting the results and applying
them to other countries, as this study was conducted in
Taiwan where the National Health Insurance covers nearly
99 % of Taiwan’s population and patients are free to access
different health care facilities, and hence affordability is
less an issue as compared to adherence of imatinib.
Conclusions
Taiwanese CML patients who are routinely followed up in
hospital generally show good adherence to imatinib.
However, patients’ misconceptions about disease progres-
sion, treatment side effects and concerns about adverse
drug reactions can jeopardise their adherence to drug
treatments. The provision of appropriate information and
patient counselling services may improve the adherence to
imatinib and patients’ outcomes, which are also possible
avenues for further research.
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Appendix: Content of the interview schedule
• Could you tell me what do you know about CML?
• Could you tell me how your CML was treated?
• Are there any treatment experiences that you would
like to talk about?
• How do you feel about the treatments that you
received?
• How do you know the treatments are working?
• How do you take your medications?
• How do you feel about the drugs that you are having?
• Are there any experiences about the drugs that
would like to talk about?
• Is there anything else that you would like to talk about?
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